{"id":314259,"date":"2025-07-19T05:00:31","date_gmt":"2025-07-19T05:00:31","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/pfizer-stock-dividend-2\/"},"modified":"2025-07-19T05:00:31","modified_gmt":"2025-07-19T05:00:31","slug":"pfizer-stock-dividend","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/","title":{"rendered":"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":259834,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16],"tags":[28,45,44],"class_list":["post-314259","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-data","tag-investment","tag-stock","tag-strategy"],"acf":{"h1":"Pfizer Hisse Senedi Temett\u00fc Performans\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Pfizer Hisse Senedi Temett\u00fc Performans\u0131"},"description":"Pfizer hisse senedi temett\u00fc analizi, benzersiz performans kal\u0131plar\u0131n\u0131 ve s\u00fcrd\u00fcr\u00fclebilirlik metriklerini ortaya koyuyor. Pocket Option ile acil portf\u00f6y kararlar\u0131 i\u00e7in \u00f6nemli bilgiler.","description_source":{"label":"Description","type":"textarea","formatted_value":"Pfizer hisse senedi temett\u00fc analizi, benzersiz performans kal\u0131plar\u0131n\u0131 ve s\u00fcrd\u00fcr\u00fclebilirlik metriklerini ortaya koyuyor. Pocket Option ile acil portf\u00f6y kararlar\u0131 i\u00e7in \u00f6nemli bilgiler."},"intro":"Eczac\u0131l\u0131k temett\u00fc yat\u0131r\u0131mlar\u0131nda gezinmek, geleneksel analizlerin s\u0131kl\u0131kla g\u00f6zden ka\u00e7\u0131rd\u0131\u011f\u0131 sekt\u00f6r spesifik dinamikler hakk\u0131nda uzmanla\u015fm\u0131\u015f bilgi gerektirir. Pfizer hisse senedi temett\u00fc \u00f6zelliklerinin bu incelemesi, yat\u0131r\u0131mc\u0131lara \u00f6deme s\u00fcrd\u00fcr\u00fclebilirli\u011fi, b\u00fcy\u00fcme projeksiyonlar\u0131 ve hem gelir \u00fcretimini hem de sermaye korunmas\u0131n\u0131 optimize eden stratejik konumland\u0131rma y\u00f6ntemleri hakk\u0131nda kritik bilgiler sunar.","intro_source":{"label":"Intro","type":"text","formatted_value":"Eczac\u0131l\u0131k temett\u00fc yat\u0131r\u0131mlar\u0131nda gezinmek, geleneksel analizlerin s\u0131kl\u0131kla g\u00f6zden ka\u00e7\u0131rd\u0131\u011f\u0131 sekt\u00f6r spesifik dinamikler hakk\u0131nda uzmanla\u015fm\u0131\u015f bilgi gerektirir. Pfizer hisse senedi temett\u00fc \u00f6zelliklerinin bu incelemesi, yat\u0131r\u0131mc\u0131lara \u00f6deme s\u00fcrd\u00fcr\u00fclebilirli\u011fi, b\u00fcy\u00fcme projeksiyonlar\u0131 ve hem gelir \u00fcretimini hem de sermaye korunmas\u0131n\u0131 optimize eden stratejik konumland\u0131rma y\u00f6ntemleri hakk\u0131nda kritik bilgiler sunar."},"body_html":"<div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Pfizer Hisse Senedi Temett\u00fc Tarihi: Evrim ve Modeller<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfizer'in kimyasal \u00fcreticisinden k\u00fcresel bir ila\u00e7 devi haline d\u00f6n\u00fc\u015f\u00fcm\u00fc, temett\u00fc evriminde yans\u0131t\u0131lmaktad\u0131r. Pfizer hisse senedi temett\u00fc tarihi, blokbaster ila\u00e7lardan biyoteknoloji yeniliklerine kadar uzanan bir\u00e7ok ila\u00e7 d\u00f6nemini kapsayan stratejik bir anlat\u0131 ortaya koymaktad\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>1901 y\u0131l\u0131nda temett\u00fc \u00f6demeye ba\u015flayan Pfizer, d\u00fcnya sava\u015flar\u0131, ekonomik buhranlar ve k\u00fcresel bir pandemiyi a\u015farak 120 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir kesintisiz \u00f6deme kayd\u0131n\u0131 s\u00fcrd\u00fcrm\u00fc\u015ft\u00fcr. Bu tutarl\u0131l\u0131k, \u015firketin finansal dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>D\u00f6nem<\/th><th>Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesi<\/th><th>Ana \u00dcr\u00fcnler<\/th><th>Temett\u00fc Stratejisi<\/th><\/tr><\/thead><tbody><tr><td>1990'lar<\/td><td>%13.2<\/td><td>Zoloft, Norvasc, Lipitor<\/td><td>H\u0131zland\u0131r\u0131lm\u0131\u015f b\u00fcy\u00fcme<\/td><\/tr><tr><td>2000-2010<\/td><td>%8.7<\/td><td>Lipitor, Viagra, Celebrex<\/td><td>Olgun b\u00fcy\u00fcme<\/td><\/tr><tr><td>2016-2019<\/td><td>%6.3<\/td><td>Ibrance, Eliquis, Xeljanz<\/td><td>Dengeli getiriler<\/td><\/tr><tr><td>2020-2023<\/td><td>%3.8<\/td><td>COVID a\u015f\u0131s\u0131, Paxlovid<\/td><td>Stabilite odakl\u0131<\/td><\/tr><tr><td>2024+<\/td><td>%2.5*<\/td><td>RSV a\u015f\u0131s\u0131, onkoloji<\/td><td>Konservatif b\u00fcy\u00fcme<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>*Mevcut temett\u00fc politikas\u0131na dayal\u0131 projeksiyon<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Veriler, mutlak \u00f6deme miktarlar\u0131 artmas\u0131na ra\u011fmen temett\u00fc b\u00fcy\u00fcme oranlar\u0131nda kademeli bir yava\u015flama oldu\u011funu ortaya koymaktad\u0131r. 1990'larda, Lipitor'un benzeri g\u00f6r\u00fclmemi\u015f nakit ak\u0131\u015flar\u0131n\u0131 y\u00f6nlendirmesiyle \u00e7ift haneli art\u0131\u015flar yayg\u0131nd\u0131. Son y\u0131llar, sekt\u00f6r\u00fcn olgunla\u015fmas\u0131n\u0131 ve Pfizer'in s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcmeye yeniden odaklanmas\u0131n\u0131 yans\u0131tan daha \u00f6l\u00e7\u00fcl\u00fc art\u0131\u015flar g\u00f6stermektedir.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>PFE Hisse Senedi Temett\u00fc S\u00fcrd\u00fcr\u00fclebilirli\u011fi: Anahtar Metrikler<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Ba\u015fl\u0131k getiri rakamlar\u0131n\u0131n \u00f6tesinde, pfe hisse senedi temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini belirleyen karma\u015f\u0131k bir finansal metrik ekosistemi bulunmaktad\u0131r. \u0130la\u00e7 \u015firketleri i\u00e7in geleneksel temett\u00fc metrikleri, Ar-Ge ihtiya\u00e7lar\u0131, patent ya\u015fam d\u00f6ng\u00fcleri ve boru hatt\u0131 verimlili\u011fini hesaba katan sekt\u00f6r spesifik g\u00f6stergelerle desteklenmelidir.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Metrik<\/th><th>Pfizer (PFE)<\/th><th>\u0130la\u00e7 Sekt\u00f6r\u00fc Ortalamas\u0131<\/th><th>Yorum<\/th><\/tr><\/thead><tbody><tr><td>Mevcut Temett\u00fc Getirisi<\/td><td>%5.4<\/td><td>%2.8<\/td><td>Ortalaman\u0131n olduk\u00e7a \u00fczerinde<\/td><\/tr><tr><td>Temett\u00fc Da\u011f\u0131t\u0131m Oran\u0131<\/td><td>%68.7<\/td><td>%51.2<\/td><td>Y\u00fcksek ama y\u00f6netilebilir<\/td><\/tr><tr><td>Serbest Nakit Ak\u0131\u015f\u0131 Kapsam\u0131<\/td><td>1.7x<\/td><td>2.1x<\/td><td>Yeterli ama ortalaman\u0131n alt\u0131nda<\/td><\/tr><tr><td>5 Y\u0131ll\u0131k Temett\u00fc Bile\u015fik B\u00fcy\u00fcme Oran\u0131<\/td><td>%4.2<\/td><td>%3.6<\/td><td>Orta derecede tutarl\u0131 b\u00fcy\u00fcme<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Bu metrikler, pfe hisse senedi temett\u00fcs\u00fcn\u00fcn sekt\u00f6r emsallerine g\u00f6re \u00e7ekici bir getiri sundu\u011funu ortaya koymaktad\u0131r. Ancak, y\u00fcksek da\u011f\u0131t\u0131m oran\u0131 ve ortalaman\u0131n alt\u0131ndaki serbest nakit ak\u0131\u015f\u0131 kapsam\u0131, \u015firketin COVID sonras\u0131 gelir normalle\u015fmesini y\u00f6netirken izlenmesi gereken unsurlard\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Finansal analistler, geleneksel metrikleri patent sona erme takvimleri, boru hatt\u0131 verimlili\u011fi ve Ar-Ge etkinli\u011fi gibi sekt\u00f6r spesifik fakt\u00f6rlerle birle\u015ftiren \u00f6zel bir \u0130la\u00e7 Temett\u00fc \u0130stikrar Endeksi geli\u015ftirmi\u015ftir. Pfizer i\u00e7in bu model, k\u0131sa vadeli bask\u0131larla birlikte orta derecede uzun vadeli s\u00fcrd\u00fcr\u00fclebilirlik g\u00f6stermektedir.<\/p><\/div><div class='po-container po-container_width_article-sm'><h3 class='po-article-page__title'>Patent U\u00e7urumu Etki De\u011ferlendirmesi<\/h3><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>\u00dcr\u00fcn<\/th><th>2023 Geliri ($B)<\/th><th>Gelir Y\u00fczdesi<\/th><th>Patent Sona Erme<\/th><th>Temett\u00fc Etkisi<\/th><\/tr><\/thead><tbody><tr><td>Eliquis<\/td><td>6.5<\/td><td>%12.3<\/td><td>2026-2028*<\/td><td>Orta<\/td><\/tr><tr><td>Prevnar Ailesi<\/td><td>5.9<\/td><td>%11.2<\/td><td>2026-2029*<\/td><td>Orta<\/td><\/tr><tr><td>Ibrance<\/td><td>4.6<\/td><td>%8.7<\/td><td>2027-2028<\/td><td>Orta<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>*Pazar ve form\u00fclasyona g\u00f6re de\u011fi\u015fir<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Bu patent sona erme takvimi, 2026-2028 y\u0131llar\u0131 aras\u0131nda \u00f6nemli gelir riskini vurgulamaktad\u0131r. 2011'deki dramatik Lipitor patent sona ermesinin aksine, bu sona ermeler daha kademeli olup, bireysel olarak toplam gelirin daha k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 temsil etmektedir ve Pfizer'e yerine ge\u00e7ecek gelir kaynaklar\u0131 geli\u015ftirmek i\u00e7in zaman tan\u0131maktad\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>PFE Hisse Senedi Fiyat\u0131 Temett\u00fc \u0130li\u015fkisi<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfe hisse senedi fiyat\u0131 temett\u00fc kararlar\u0131 ve piyasa de\u011ferlemesi aras\u0131ndaki etkile\u015fim, dinamik bir geri bildirim sistemi yarat\u0131r. Tarihsel analiz, Pfizer'in temett\u00fc politikas\u0131n\u0131n hisse senedi fiyat\u0131n\u0131 nas\u0131l etkiledi\u011fine dair \u00f6nemli modelleri ortaya koymaktad\u0131r:<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Temett\u00fc Olay\u0131<\/th><th>Piyasa Ko\u015fulu<\/th><th>Fiyat Tepkisi (30 g\u00fcn)<\/th><\/tr><\/thead><tbody><tr><td>Beklentilerin \u00fczerinde art\u0131\u015f<\/td><td>Bo\u011fa piyasas\u0131<\/td><td>+%2.1 ila +%4.3<\/td><\/tr><tr><td>Beklentilerin \u00fczerinde art\u0131\u015f<\/td><td>Ay\u0131 piyasas\u0131<\/td><td>+%4.7 ila +%7.2<\/td><\/tr><tr><td>Beklentilerin alt\u0131nda art\u0131\u015f<\/td><td>Ay\u0131 piyasas\u0131<\/td><td>-%6.7 ila -%9.5<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Bu veriler, pfe hisse senedi fiyat\u0131 temett\u00fc duyarl\u0131l\u0131\u011f\u0131n\u0131n piyasa ko\u015fullar\u0131na ba\u011fl\u0131 olarak \u00f6nemli \u00f6l\u00e7\u00fcde de\u011fi\u015fti\u011fini g\u00f6stermektedir. Temett\u00fc sinyalleri, piyasa stresi d\u00f6nemlerinde daha b\u00fcy\u00fck a\u011f\u0131rl\u0131k ta\u015f\u0131r ve art\u0131\u015flar, ay\u0131 piyasalar\u0131nda g\u00fc\u00e7l\u00fc g\u00fcven sinyalleri olarak hizmet ederek a\u015f\u0131r\u0131 olumlu fiyat tepkileri \u00fcretir.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfizer'in yakla\u015f\u0131k %5.4'l\u00fck mevcut getirisi, genellikle d\u00fc\u015f\u00fck de\u011ferleme g\u00f6steren tarihsel \"\u00f6nemli k\u00f6t\u00fcmserlik\" aral\u0131\u011f\u0131nda yer almaktad\u0131r. Pocket Option piyasa analizi, bu getiri bazl\u0131 d\u00fc\u015f\u00fck de\u011ferleme sinyalinin, yak\u0131n vadeli gelir zorluklar\u0131 taraf\u0131ndan k\u0131smen dengelendi\u011fini ve dengeli bir risk-getiri profili olu\u015fturdu\u011funu belirtmektedir.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>PFE Hisse Senedi Temett\u00fc Tarihi Stratejileri<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Gelir odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in pfe hisse senedi temett\u00fc tarihi, kritik bir takvim d\u00f6n\u00fcm noktas\u0131d\u0131r. Pfizer, Mart, Haziran, Eyl\u00fcl ve Aral\u0131k aylar\u0131nda \u00f6demelerle \u00fc\u00e7 ayl\u0131k bir temett\u00fc takvimi izler ve her \u00f6deme \u00f6ncesi yakla\u015f\u0131k iki hafta \u00f6nce temett\u00fc tarihleri belirlenir.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Tarihsel veriler, Pfizer'in temett\u00fc tarihleri etraf\u0131ndaki fiyat davran\u0131\u015f\u0131nda belirgin modeller ortaya koymaktad\u0131r:<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Zaman D\u00f6nemi<\/th><th>Ortalama Fiyat Davran\u0131\u015f\u0131<\/th><th>Stratejik \u0130mplikasyon<\/th><\/tr><\/thead><tbody><tr><td>Temett\u00fc tarihinden 5-1 g\u00fcn \u00f6nce<\/td><td>+%1.2 g\u00f6receli performans<\/td><td>Temett\u00fc \u00f6ncesi g\u00fc\u00e7<\/td><\/tr><tr><td>Temett\u00fc tarihi<\/td><td>-%1.1 (temett\u00fc ayarl\u0131)<\/td><td>Beklenen mekanik ayarlama<\/td><\/tr><tr><td>Temett\u00fc tarihinden 1-5 g\u00fcn sonra<\/td><td>-%0.6 g\u00f6receli performans<\/td><td>Temett\u00fc sonras\u0131 zay\u0131fl\u0131k<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Bu modeller, giri\u015f ve \u00e7\u0131k\u0131\u015f noktalar\u0131n\u0131 optimize etmek i\u00e7in f\u0131rsat pencereleri ortaya koymaktad\u0131r. En dikkat \u00e7ekici model, temett\u00fc tarihinden \u00f6nceki s\u00fcrekli g\u00fc\u00e7 ve sonras\u0131ndaki zay\u0131fl\u0131kt\u0131r. Bu, saf temett\u00fc yakalama stratejilerinin daha sofistike yakla\u015f\u0131mlara g\u00f6re d\u00fc\u015f\u00fck performans g\u00f6sterebilece\u011fini \u00f6nermektedir.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option ticaret uzmanlar\u0131, temett\u00fc tarihinden \u00f6nce kademeli pozisyon birikimi ve temett\u00fc sonras\u0131 zay\u0131fl\u0131k sonras\u0131 stratejik yeniden giri\u015f gibi geli\u015fmi\u015f stratejiler \u00f6nermektedir. Bu stratejilerin etkinli\u011fi piyasa oynakl\u0131\u011f\u0131 ile de\u011fi\u015fir ve en g\u00fc\u00e7l\u00fc sinyaller sakin piyasa d\u00f6nemlerinde ortaya \u00e7\u0131kar.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Pfizer Hisse Senedi Temett\u00fcs\u00fc ile Portf\u00f6y Olu\u015fturma<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfizer hisse senedi temett\u00fcs\u00fc genellikle bir gelir \u00fcretim merce\u011finden g\u00f6r\u00fclse de, sofistike portf\u00f6y y\u00f6neticileri \u00e7ok boyutlu rol\u00fcn\u00fc tan\u0131r. Getirinin \u00f6tesinde, Pfizer'in temett\u00fc \u00f6zellikleri birka\u00e7 farkl\u0131 mekanizma arac\u0131l\u0131\u011f\u0131yla katk\u0131da bulunur:<\/p><\/div><div class='po-container po-container_width_article-sm article-content po-article-page__text'><ul class='po-article-page-list'><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Ana Gelir \u00dcreticisi: Gelir portf\u00f6ylerinde %3-5 tahsis, \u00fc\u00e7 ayl\u0131k \u00f6demelerle ortalaman\u0131n \u00fczerinde getiri sa\u011flar<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Defansif Pozisyon: B\u00fcy\u00fcme portf\u00f6ylerinde %1-3 tahsis, daha d\u00fc\u015f\u00fck beta ve piyasa stresi s\u0131ras\u0131nda azalan d\u00fc\u015f\u00fc\u015fler sunar<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Enflasyon Korumas\u0131: Enflasyona duyarl\u0131 portf\u00f6ylerde %2-4 tahsis, ila\u00e7 fiyatland\u0131rma g\u00fcc\u00fcnden yararlan\u0131r<\/li><\/ul><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Bu \u00e7ok boyutlu yakla\u015f\u0131m, 2000 y\u0131l\u0131ndan bu yana en b\u00fcy\u00fck on piyasa d\u00fc\u015f\u00fc\u015f\u00fc s\u0131ras\u0131nda ortalama %8.7'lik bir \u00fcst\u00fcn performans sa\u011flayan Pfizer'in kar\u015f\u0131 d\u00f6ng\u00fcsel e\u011filimini tan\u0131r. Bu, daha d\u00f6ng\u00fcsel olarak hassas pozisyonlarla birle\u015ftirildi\u011finde do\u011fal portf\u00f6y koruma etkileri yarat\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Gelecek G\u00f6r\u00fcn\u00fcm: Pfizer Hisse Senedi Temett\u00fc Y\u00f6r\u00fcngesi<\/h2><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Zaman \u00c7er\u00e7evesi<\/th><th>Gelir Tahmini<\/th><th>\u00d6ng\u00f6r\u00fclen Temett\u00fc B\u00fcy\u00fcmesi<\/th><th>Anahtar S\u00fcr\u00fcc\u00fcler<\/th><\/tr><\/thead><tbody><tr><td>K\u0131sa vadeli (1-2 y\u0131l)<\/td><td>-%15 ila -%20<\/td><td>Y\u0131ll\u0131k %1-2<\/td><td>COVID sonras\u0131 normalle\u015fme<\/td><\/tr><tr><td>Orta vadeli (3-5 y\u0131l)<\/td><td>+%3 ila +%5<\/td><td>Y\u0131ll\u0131k %3-4<\/td><td>Yeni \u00fcr\u00fcn lansmanlar\u0131<\/td><\/tr><tr><td>Uzun vadeli (6-10 y\u0131l)<\/td><td>+%4 ila +%7<\/td><td>Y\u0131ll\u0131k %4-6<\/td><td>Boru hatt\u0131 olgunla\u015fmas\u0131<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Bu \u00f6ng\u00f6r\u00fclen b\u00fcy\u00fcme modeli, Pfizer'in ge\u00e7i\u015f a\u015famas\u0131n\u0131 yans\u0131t\u0131r ve m\u00fctevaz\u0131 k\u0131sa vadeli art\u0131\u015flar, pandemi sonras\u0131 strateji olgunla\u015ft\u0131k\u00e7a daha g\u00fc\u00e7l\u00fc b\u00fcy\u00fcmeye yol a\u00e7ar. Anahtar etkileyen fakt\u00f6rler aras\u0131nda RSV a\u015f\u0131s\u0131n\u0131n ticarile\u015ftirilmesi, Seagen sat\u0131n al\u0131m entegrasyonu ve patent sona erme y\u00f6netimi yer al\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option finansal analistleri, bu temett\u00fc y\u00f6r\u00fcngesinin Pfizer'i y\u00fcksek getiri\/d\u00fc\u015f\u00fck b\u00fcy\u00fcme hizmetleri ve d\u00fc\u015f\u00fck getiri\/y\u00fcksek b\u00fcy\u00fcme teknoloji \u015firketleri aras\u0131nda konumland\u0131rd\u0131\u011f\u0131n\u0131 belirtmektedir. Bu dengeli profil, uzun vadeli b\u00fcy\u00fcme potansiyelinden \u00f6d\u00fcn vermeden anlaml\u0131 mevcut gelir arayan yat\u0131r\u0131mc\u0131lara hitap eder.<\/p><\/div>[cta_button text=\"\"]<div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Sonu\u00e7: Pfizer Hisse Senedi Temett\u00fc Yat\u0131r\u0131mlar\u0131nda Stratejik Konumland\u0131rma<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pfizer hisse senedi temett\u00fc f\u0131rsat\u0131, basit getiri hesaplamalar\u0131n\u0131n \u00f6tesinde \u00e7ok y\u00f6nl\u00fc bir yat\u0131r\u0131m durumu sunmaktad\u0131r. Yat\u0131r\u0131mc\u0131lar i\u00e7in birka\u00e7 somut sonu\u00e7 ortaya \u00e7\u0131kmaktad\u0131r:<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>\u0130lk olarak, Pfizer'in mevcut %5.4'l\u00fck temett\u00fc getirisi, COVID sonras\u0131 gelir ge\u00e7i\u015fine ili\u015fkin piyasa k\u00f6t\u00fcmserli\u011fini yans\u0131tmaktad\u0131r. Tarihsel modeller, bu y\u00fcksek getirinin tipik olarak d\u00fc\u015f\u00fck de\u011ferlemeyi g\u00f6sterdi\u011fini, ancak pandemi ile ilgili bozulmalar\u0131n karma\u015f\u0131kl\u0131k ekledi\u011fini \u00f6nermektedir.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>\u0130kinci olarak, temett\u00fc temelleri, gelir kar\u015f\u0131t\u0131 r\u00fczgarlara ra\u011fmen sa\u011flam kalmakta ve y\u00f6netim temett\u00fc bak\u0131m\u0131na ba\u011fl\u0131l\u0131k g\u00f6stermektedir. Y\u00fcksek da\u011f\u0131t\u0131m oran\u0131, \u00f6nemli k\u0131sa vadeli art\u0131\u015flar i\u00e7in s\u0131n\u0131rl\u0131 alan \u00f6nerse de, g\u00fc\u00e7l\u00fc bilan\u00e7o kesintilere kar\u015f\u0131 bir tampon sa\u011flar.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>\u00dc\u00e7\u00fcnc\u00fc olarak, optimal konumland\u0131rma, temett\u00fc tarihi modellerinden yararlanan sofistike takvim tabanl\u0131 stratejileri i\u00e7ermeyi gerektirir ve giri\u015f ve \u00e7\u0131k\u0131\u015flar\u0131 stratejik olarak zamanlayan yat\u0131r\u0131mc\u0131lar i\u00e7in getirileri art\u0131r\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Son olarak, en \u00e7ekici yakla\u015f\u0131m, Pfizer'i ortalaman\u0131n \u00fczerinde gelir, defansif konumland\u0131rma, enflasyon direnci ve daha d\u00fc\u015f\u00fck volatilite sa\u011fl\u0131k hizmeti maruziyeti gibi bir\u00e7ok faydal\u0131 \u00f6zellik sunan stratejik bir portf\u00f6y bile\u015feni olarak g\u00f6rmektir.<\/p><\/div>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Pfizer Hisse Senedi Temett\u00fc Tarihi: Evrim ve Modeller<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfizer&#8217;in kimyasal \u00fcreticisinden k\u00fcresel bir ila\u00e7 devi haline d\u00f6n\u00fc\u015f\u00fcm\u00fc, temett\u00fc evriminde yans\u0131t\u0131lmaktad\u0131r. Pfizer hisse senedi temett\u00fc tarihi, blokbaster ila\u00e7lardan biyoteknoloji yeniliklerine kadar uzanan bir\u00e7ok ila\u00e7 d\u00f6nemini kapsayan stratejik bir anlat\u0131 ortaya koymaktad\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>1901 y\u0131l\u0131nda temett\u00fc \u00f6demeye ba\u015flayan Pfizer, d\u00fcnya sava\u015flar\u0131, ekonomik buhranlar ve k\u00fcresel bir pandemiyi a\u015farak 120 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir kesintisiz \u00f6deme kayd\u0131n\u0131 s\u00fcrd\u00fcrm\u00fc\u015ft\u00fcr. Bu tutarl\u0131l\u0131k, \u015firketin finansal dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>D\u00f6nem<\/th>\n<th>Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesi<\/th>\n<th>Ana \u00dcr\u00fcnler<\/th>\n<th>Temett\u00fc Stratejisi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1990&#8217;lar<\/td>\n<td>%13.2<\/td>\n<td>Zoloft, Norvasc, Lipitor<\/td>\n<td>H\u0131zland\u0131r\u0131lm\u0131\u015f b\u00fcy\u00fcme<\/td>\n<\/tr>\n<tr>\n<td>2000-2010<\/td>\n<td>%8.7<\/td>\n<td>Lipitor, Viagra, Celebrex<\/td>\n<td>Olgun b\u00fcy\u00fcme<\/td>\n<\/tr>\n<tr>\n<td>2016-2019<\/td>\n<td>%6.3<\/td>\n<td>Ibrance, Eliquis, Xeljanz<\/td>\n<td>Dengeli getiriler<\/td>\n<\/tr>\n<tr>\n<td>2020-2023<\/td>\n<td>%3.8<\/td>\n<td>COVID a\u015f\u0131s\u0131, Paxlovid<\/td>\n<td>Stabilite odakl\u0131<\/td>\n<\/tr>\n<tr>\n<td>2024+<\/td>\n<td>%2.5*<\/td>\n<td>RSV a\u015f\u0131s\u0131, onkoloji<\/td>\n<td>Konservatif b\u00fcy\u00fcme<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>*Mevcut temett\u00fc politikas\u0131na dayal\u0131 projeksiyon<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Veriler, mutlak \u00f6deme miktarlar\u0131 artmas\u0131na ra\u011fmen temett\u00fc b\u00fcy\u00fcme oranlar\u0131nda kademeli bir yava\u015flama oldu\u011funu ortaya koymaktad\u0131r. 1990&#8217;larda, Lipitor&#8217;un benzeri g\u00f6r\u00fclmemi\u015f nakit ak\u0131\u015flar\u0131n\u0131 y\u00f6nlendirmesiyle \u00e7ift haneli art\u0131\u015flar yayg\u0131nd\u0131. Son y\u0131llar, sekt\u00f6r\u00fcn olgunla\u015fmas\u0131n\u0131 ve Pfizer&#8217;in s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcmeye yeniden odaklanmas\u0131n\u0131 yans\u0131tan daha \u00f6l\u00e7\u00fcl\u00fc art\u0131\u015flar g\u00f6stermektedir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>PFE Hisse Senedi Temett\u00fc S\u00fcrd\u00fcr\u00fclebilirli\u011fi: Anahtar Metrikler<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Ba\u015fl\u0131k getiri rakamlar\u0131n\u0131n \u00f6tesinde, pfe hisse senedi temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini belirleyen karma\u015f\u0131k bir finansal metrik ekosistemi bulunmaktad\u0131r. \u0130la\u00e7 \u015firketleri i\u00e7in geleneksel temett\u00fc metrikleri, Ar-Ge ihtiya\u00e7lar\u0131, patent ya\u015fam d\u00f6ng\u00fcleri ve boru hatt\u0131 verimlili\u011fini hesaba katan sekt\u00f6r spesifik g\u00f6stergelerle desteklenmelidir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Metrik<\/th>\n<th>Pfizer (PFE)<\/th>\n<th>\u0130la\u00e7 Sekt\u00f6r\u00fc Ortalamas\u0131<\/th>\n<th>Yorum<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mevcut Temett\u00fc Getirisi<\/td>\n<td>%5.4<\/td>\n<td>%2.8<\/td>\n<td>Ortalaman\u0131n olduk\u00e7a \u00fczerinde<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Da\u011f\u0131t\u0131m Oran\u0131<\/td>\n<td>%68.7<\/td>\n<td>%51.2<\/td>\n<td>Y\u00fcksek ama y\u00f6netilebilir<\/td>\n<\/tr>\n<tr>\n<td>Serbest Nakit Ak\u0131\u015f\u0131 Kapsam\u0131<\/td>\n<td>1.7x<\/td>\n<td>2.1x<\/td>\n<td>Yeterli ama ortalaman\u0131n alt\u0131nda<\/td>\n<\/tr>\n<tr>\n<td>5 Y\u0131ll\u0131k Temett\u00fc Bile\u015fik B\u00fcy\u00fcme Oran\u0131<\/td>\n<td>%4.2<\/td>\n<td>%3.6<\/td>\n<td>Orta derecede tutarl\u0131 b\u00fcy\u00fcme<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Bu metrikler, pfe hisse senedi temett\u00fcs\u00fcn\u00fcn sekt\u00f6r emsallerine g\u00f6re \u00e7ekici bir getiri sundu\u011funu ortaya koymaktad\u0131r. Ancak, y\u00fcksek da\u011f\u0131t\u0131m oran\u0131 ve ortalaman\u0131n alt\u0131ndaki serbest nakit ak\u0131\u015f\u0131 kapsam\u0131, \u015firketin COVID sonras\u0131 gelir normalle\u015fmesini y\u00f6netirken izlenmesi gereken unsurlard\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Finansal analistler, geleneksel metrikleri patent sona erme takvimleri, boru hatt\u0131 verimlili\u011fi ve Ar-Ge etkinli\u011fi gibi sekt\u00f6r spesifik fakt\u00f6rlerle birle\u015ftiren \u00f6zel bir \u0130la\u00e7 Temett\u00fc \u0130stikrar Endeksi geli\u015ftirmi\u015ftir. Pfizer i\u00e7in bu model, k\u0131sa vadeli bask\u0131larla birlikte orta derecede uzun vadeli s\u00fcrd\u00fcr\u00fclebilirlik g\u00f6stermektedir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h3 class='po-article-page__title'>Patent U\u00e7urumu Etki De\u011ferlendirmesi<\/h3>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>\u00dcr\u00fcn<\/th>\n<th>2023 Geliri ($B)<\/th>\n<th>Gelir Y\u00fczdesi<\/th>\n<th>Patent Sona Erme<\/th>\n<th>Temett\u00fc Etkisi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Eliquis<\/td>\n<td>6.5<\/td>\n<td>%12.3<\/td>\n<td>2026-2028*<\/td>\n<td>Orta<\/td>\n<\/tr>\n<tr>\n<td>Prevnar Ailesi<\/td>\n<td>5.9<\/td>\n<td>%11.2<\/td>\n<td>2026-2029*<\/td>\n<td>Orta<\/td>\n<\/tr>\n<tr>\n<td>Ibrance<\/td>\n<td>4.6<\/td>\n<td>%8.7<\/td>\n<td>2027-2028<\/td>\n<td>Orta<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>*Pazar ve form\u00fclasyona g\u00f6re de\u011fi\u015fir<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Bu patent sona erme takvimi, 2026-2028 y\u0131llar\u0131 aras\u0131nda \u00f6nemli gelir riskini vurgulamaktad\u0131r. 2011&#8217;deki dramatik Lipitor patent sona ermesinin aksine, bu sona ermeler daha kademeli olup, bireysel olarak toplam gelirin daha k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 temsil etmektedir ve Pfizer&#8217;e yerine ge\u00e7ecek gelir kaynaklar\u0131 geli\u015ftirmek i\u00e7in zaman tan\u0131maktad\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>PFE Hisse Senedi Fiyat\u0131 Temett\u00fc \u0130li\u015fkisi<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfe hisse senedi fiyat\u0131 temett\u00fc kararlar\u0131 ve piyasa de\u011ferlemesi aras\u0131ndaki etkile\u015fim, dinamik bir geri bildirim sistemi yarat\u0131r. Tarihsel analiz, Pfizer&#8217;in temett\u00fc politikas\u0131n\u0131n hisse senedi fiyat\u0131n\u0131 nas\u0131l etkiledi\u011fine dair \u00f6nemli modelleri ortaya koymaktad\u0131r:<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Temett\u00fc Olay\u0131<\/th>\n<th>Piyasa Ko\u015fulu<\/th>\n<th>Fiyat Tepkisi (30 g\u00fcn)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Beklentilerin \u00fczerinde art\u0131\u015f<\/td>\n<td>Bo\u011fa piyasas\u0131<\/td>\n<td>+%2.1 ila +%4.3<\/td>\n<\/tr>\n<tr>\n<td>Beklentilerin \u00fczerinde art\u0131\u015f<\/td>\n<td>Ay\u0131 piyasas\u0131<\/td>\n<td>+%4.7 ila +%7.2<\/td>\n<\/tr>\n<tr>\n<td>Beklentilerin alt\u0131nda art\u0131\u015f<\/td>\n<td>Ay\u0131 piyasas\u0131<\/td>\n<td>-%6.7 ila -%9.5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Bu veriler, pfe hisse senedi fiyat\u0131 temett\u00fc duyarl\u0131l\u0131\u011f\u0131n\u0131n piyasa ko\u015fullar\u0131na ba\u011fl\u0131 olarak \u00f6nemli \u00f6l\u00e7\u00fcde de\u011fi\u015fti\u011fini g\u00f6stermektedir. Temett\u00fc sinyalleri, piyasa stresi d\u00f6nemlerinde daha b\u00fcy\u00fck a\u011f\u0131rl\u0131k ta\u015f\u0131r ve art\u0131\u015flar, ay\u0131 piyasalar\u0131nda g\u00fc\u00e7l\u00fc g\u00fcven sinyalleri olarak hizmet ederek a\u015f\u0131r\u0131 olumlu fiyat tepkileri \u00fcretir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfizer&#8217;in yakla\u015f\u0131k %5.4&#8217;l\u00fck mevcut getirisi, genellikle d\u00fc\u015f\u00fck de\u011ferleme g\u00f6steren tarihsel &#8220;\u00f6nemli k\u00f6t\u00fcmserlik&#8221; aral\u0131\u011f\u0131nda yer almaktad\u0131r. Pocket Option piyasa analizi, bu getiri bazl\u0131 d\u00fc\u015f\u00fck de\u011ferleme sinyalinin, yak\u0131n vadeli gelir zorluklar\u0131 taraf\u0131ndan k\u0131smen dengelendi\u011fini ve dengeli bir risk-getiri profili olu\u015fturdu\u011funu belirtmektedir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>PFE Hisse Senedi Temett\u00fc Tarihi Stratejileri<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Gelir odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in pfe hisse senedi temett\u00fc tarihi, kritik bir takvim d\u00f6n\u00fcm noktas\u0131d\u0131r. Pfizer, Mart, Haziran, Eyl\u00fcl ve Aral\u0131k aylar\u0131nda \u00f6demelerle \u00fc\u00e7 ayl\u0131k bir temett\u00fc takvimi izler ve her \u00f6deme \u00f6ncesi yakla\u015f\u0131k iki hafta \u00f6nce temett\u00fc tarihleri belirlenir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Tarihsel veriler, Pfizer&#8217;in temett\u00fc tarihleri etraf\u0131ndaki fiyat davran\u0131\u015f\u0131nda belirgin modeller ortaya koymaktad\u0131r:<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Zaman D\u00f6nemi<\/th>\n<th>Ortalama Fiyat Davran\u0131\u015f\u0131<\/th>\n<th>Stratejik \u0130mplikasyon<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Temett\u00fc tarihinden 5-1 g\u00fcn \u00f6nce<\/td>\n<td>+%1.2 g\u00f6receli performans<\/td>\n<td>Temett\u00fc \u00f6ncesi g\u00fc\u00e7<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc tarihi<\/td>\n<td>-%1.1 (temett\u00fc ayarl\u0131)<\/td>\n<td>Beklenen mekanik ayarlama<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc tarihinden 1-5 g\u00fcn sonra<\/td>\n<td>-%0.6 g\u00f6receli performans<\/td>\n<td>Temett\u00fc sonras\u0131 zay\u0131fl\u0131k<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Bu modeller, giri\u015f ve \u00e7\u0131k\u0131\u015f noktalar\u0131n\u0131 optimize etmek i\u00e7in f\u0131rsat pencereleri ortaya koymaktad\u0131r. En dikkat \u00e7ekici model, temett\u00fc tarihinden \u00f6nceki s\u00fcrekli g\u00fc\u00e7 ve sonras\u0131ndaki zay\u0131fl\u0131kt\u0131r. Bu, saf temett\u00fc yakalama stratejilerinin daha sofistike yakla\u015f\u0131mlara g\u00f6re d\u00fc\u015f\u00fck performans g\u00f6sterebilece\u011fini \u00f6nermektedir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option ticaret uzmanlar\u0131, temett\u00fc tarihinden \u00f6nce kademeli pozisyon birikimi ve temett\u00fc sonras\u0131 zay\u0131fl\u0131k sonras\u0131 stratejik yeniden giri\u015f gibi geli\u015fmi\u015f stratejiler \u00f6nermektedir. Bu stratejilerin etkinli\u011fi piyasa oynakl\u0131\u011f\u0131 ile de\u011fi\u015fir ve en g\u00fc\u00e7l\u00fc sinyaller sakin piyasa d\u00f6nemlerinde ortaya \u00e7\u0131kar.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Pfizer Hisse Senedi Temett\u00fcs\u00fc ile Portf\u00f6y Olu\u015fturma<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfizer hisse senedi temett\u00fcs\u00fc genellikle bir gelir \u00fcretim merce\u011finden g\u00f6r\u00fclse de, sofistike portf\u00f6y y\u00f6neticileri \u00e7ok boyutlu rol\u00fcn\u00fc tan\u0131r. Getirinin \u00f6tesinde, Pfizer&#8217;in temett\u00fc \u00f6zellikleri birka\u00e7 farkl\u0131 mekanizma arac\u0131l\u0131\u011f\u0131yla katk\u0131da bulunur:<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm article-content po-article-page__text'>\n<ul class='po-article-page-list'>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Ana Gelir \u00dcreticisi: Gelir portf\u00f6ylerinde %3-5 tahsis, \u00fc\u00e7 ayl\u0131k \u00f6demelerle ortalaman\u0131n \u00fczerinde getiri sa\u011flar<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Defansif Pozisyon: B\u00fcy\u00fcme portf\u00f6ylerinde %1-3 tahsis, daha d\u00fc\u015f\u00fck beta ve piyasa stresi s\u0131ras\u0131nda azalan d\u00fc\u015f\u00fc\u015fler sunar<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Enflasyon Korumas\u0131: Enflasyona duyarl\u0131 portf\u00f6ylerde %2-4 tahsis, ila\u00e7 fiyatland\u0131rma g\u00fcc\u00fcnden yararlan\u0131r<\/li>\n<\/ul>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Bu \u00e7ok boyutlu yakla\u015f\u0131m, 2000 y\u0131l\u0131ndan bu yana en b\u00fcy\u00fck on piyasa d\u00fc\u015f\u00fc\u015f\u00fc s\u0131ras\u0131nda ortalama %8.7&#8217;lik bir \u00fcst\u00fcn performans sa\u011flayan Pfizer&#8217;in kar\u015f\u0131 d\u00f6ng\u00fcsel e\u011filimini tan\u0131r. Bu, daha d\u00f6ng\u00fcsel olarak hassas pozisyonlarla birle\u015ftirildi\u011finde do\u011fal portf\u00f6y koruma etkileri yarat\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Gelecek G\u00f6r\u00fcn\u00fcm: Pfizer Hisse Senedi Temett\u00fc Y\u00f6r\u00fcngesi<\/h2>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Zaman \u00c7er\u00e7evesi<\/th>\n<th>Gelir Tahmini<\/th>\n<th>\u00d6ng\u00f6r\u00fclen Temett\u00fc B\u00fcy\u00fcmesi<\/th>\n<th>Anahtar S\u00fcr\u00fcc\u00fcler<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>K\u0131sa vadeli (1-2 y\u0131l)<\/td>\n<td>-%15 ila -%20<\/td>\n<td>Y\u0131ll\u0131k %1-2<\/td>\n<td>COVID sonras\u0131 normalle\u015fme<\/td>\n<\/tr>\n<tr>\n<td>Orta vadeli (3-5 y\u0131l)<\/td>\n<td>+%3 ila +%5<\/td>\n<td>Y\u0131ll\u0131k %3-4<\/td>\n<td>Yeni \u00fcr\u00fcn lansmanlar\u0131<\/td>\n<\/tr>\n<tr>\n<td>Uzun vadeli (6-10 y\u0131l)<\/td>\n<td>+%4 ila +%7<\/td>\n<td>Y\u0131ll\u0131k %4-6<\/td>\n<td>Boru hatt\u0131 olgunla\u015fmas\u0131<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Bu \u00f6ng\u00f6r\u00fclen b\u00fcy\u00fcme modeli, Pfizer&#8217;in ge\u00e7i\u015f a\u015famas\u0131n\u0131 yans\u0131t\u0131r ve m\u00fctevaz\u0131 k\u0131sa vadeli art\u0131\u015flar, pandemi sonras\u0131 strateji olgunla\u015ft\u0131k\u00e7a daha g\u00fc\u00e7l\u00fc b\u00fcy\u00fcmeye yol a\u00e7ar. Anahtar etkileyen fakt\u00f6rler aras\u0131nda RSV a\u015f\u0131s\u0131n\u0131n ticarile\u015ftirilmesi, Seagen sat\u0131n al\u0131m entegrasyonu ve patent sona erme y\u00f6netimi yer al\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option finansal analistleri, bu temett\u00fc y\u00f6r\u00fcngesinin Pfizer&#8217;i y\u00fcksek getiri\/d\u00fc\u015f\u00fck b\u00fcy\u00fcme hizmetleri ve d\u00fc\u015f\u00fck getiri\/y\u00fcksek b\u00fcy\u00fcme teknoloji \u015firketleri aras\u0131nda konumland\u0131rd\u0131\u011f\u0131n\u0131 belirtmektedir. Bu dengeli profil, uzun vadeli b\u00fcy\u00fcme potansiyelinden \u00f6d\u00fcn vermeden anlaml\u0131 mevcut gelir arayan yat\u0131r\u0131mc\u0131lara hitap eder.<\/p>\n<\/div>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\"><\/span>\n        <\/a>\n    <\/div>\n    \n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Sonu\u00e7: Pfizer Hisse Senedi Temett\u00fc Yat\u0131r\u0131mlar\u0131nda Stratejik Konumland\u0131rma<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pfizer hisse senedi temett\u00fc f\u0131rsat\u0131, basit getiri hesaplamalar\u0131n\u0131n \u00f6tesinde \u00e7ok y\u00f6nl\u00fc bir yat\u0131r\u0131m durumu sunmaktad\u0131r. Yat\u0131r\u0131mc\u0131lar i\u00e7in birka\u00e7 somut sonu\u00e7 ortaya \u00e7\u0131kmaktad\u0131r:<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>\u0130lk olarak, Pfizer&#8217;in mevcut %5.4&#8217;l\u00fck temett\u00fc getirisi, COVID sonras\u0131 gelir ge\u00e7i\u015fine ili\u015fkin piyasa k\u00f6t\u00fcmserli\u011fini yans\u0131tmaktad\u0131r. Tarihsel modeller, bu y\u00fcksek getirinin tipik olarak d\u00fc\u015f\u00fck de\u011ferlemeyi g\u00f6sterdi\u011fini, ancak pandemi ile ilgili bozulmalar\u0131n karma\u015f\u0131kl\u0131k ekledi\u011fini \u00f6nermektedir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>\u0130kinci olarak, temett\u00fc temelleri, gelir kar\u015f\u0131t\u0131 r\u00fczgarlara ra\u011fmen sa\u011flam kalmakta ve y\u00f6netim temett\u00fc bak\u0131m\u0131na ba\u011fl\u0131l\u0131k g\u00f6stermektedir. Y\u00fcksek da\u011f\u0131t\u0131m oran\u0131, \u00f6nemli k\u0131sa vadeli art\u0131\u015flar i\u00e7in s\u0131n\u0131rl\u0131 alan \u00f6nerse de, g\u00fc\u00e7l\u00fc bilan\u00e7o kesintilere kar\u015f\u0131 bir tampon sa\u011flar.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>\u00dc\u00e7\u00fcnc\u00fc olarak, optimal konumland\u0131rma, temett\u00fc tarihi modellerinden yararlanan sofistike takvim tabanl\u0131 stratejileri i\u00e7ermeyi gerektirir ve giri\u015f ve \u00e7\u0131k\u0131\u015flar\u0131 stratejik olarak zamanlayan yat\u0131r\u0131mc\u0131lar i\u00e7in getirileri art\u0131r\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Son olarak, en \u00e7ekici yakla\u015f\u0131m, Pfizer&#8217;i ortalaman\u0131n \u00fczerinde gelir, defansif konumland\u0131rma, enflasyon direnci ve daha d\u00fc\u015f\u00fck volatilite sa\u011fl\u0131k hizmeti maruziyeti gibi bir\u00e7ok faydal\u0131 \u00f6zellik sunan stratejik bir portf\u00f6y bile\u015feni olarak g\u00f6rmektir.<\/p>\n<\/div>\n"},"faq":[{"question":"Mevcut PFE hisse senedi temett\u00fc getirisi nedir?","answer":"Mevcut pfe hisse senedi temett\u00fc getirisi yakla\u015f\u0131k %5,4 seviyesinde olup, bu oran hem ila\u00e7 end\u00fcstrisi ortalamas\u0131 olan %2,8'in hem de S&P 500 ortalamas\u0131 olan %1,5'in olduk\u00e7a \u00fczerindedir. Bu y\u00fcksek getiri, Pfizer'\u0131n hissedar getirilerine olan ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 ve COVID sonras\u0131 gelir normalle\u015fmesiyle ilgili hisse fiyat\u0131 bask\u0131s\u0131n\u0131 yans\u0131tmaktad\u0131r. \u015eirket \u015fu anda \u00e7eyrek ba\u015f\u0131na hisse ba\u015f\u0131na 0,42 $ \u00f6demekte olup, bu y\u0131ll\u0131k 1,68 $'a denk gelmektedir. Bu ortalaman\u0131n \u00fczerindeki getiri, Pfizer'\u0131 piyasadaki en y\u00fcksek getirili b\u00fcy\u00fck \u00f6l\u00e7ekli ila\u00e7 hisseleri aras\u0131nda konumland\u0131rmaktad\u0131r."},{"question":"Bir sonraki pfe hisse senedi temett\u00fc \u00f6deme tarihi ne zaman?","answer":"Pfizer, Mart, Haziran, Eyl\u00fcl ve Aral\u0131k aylar\u0131nda \u00f6demelerle \u00fc\u00e7 ayl\u0131k bir temett\u00fc program\u0131 izler. Kesin pfe hisse senedi temett\u00fc tarihinden \u00f6nceki tarih her \u00e7eyrekte de\u011fi\u015fiklik g\u00f6sterir, ancak genellikle \u00f6deme tarihinden yakla\u015f\u0131k iki hafta \u00f6nce ger\u00e7ekle\u015fir. En g\u00fcncel bilgiler i\u00e7in yat\u0131r\u0131mc\u0131lar, bir sonraki temett\u00fc tarihinden \u00f6nce Pfizer'\u0131n yat\u0131r\u0131mc\u0131 ili\u015fkileri web sitesini veya finansal veri sa\u011flay\u0131c\u0131lar\u0131n\u0131 kontrol etmelidir. \u015eirket, temett\u00fc tarihlerini \u00f6nceden duyurma konusunda tutarl\u0131 bir ge\u00e7mi\u015fe sahiptir ve bu da yat\u0131r\u0131mc\u0131lar\u0131n takvim bazl\u0131 stratejiler planlamas\u0131na olanak tan\u0131r."},{"question":"Pfizer hisse senedi temett\u00fc ge\u00e7mi\u015fi zamanla nas\u0131l de\u011fi\u015fti?","answer":"Pfizer hisse senedi temett\u00fc ge\u00e7mi\u015fi, on y\u0131llar boyunca dikkate de\u011fer bir tutarl\u0131l\u0131k ve b\u00fcy\u00fcme g\u00f6stermektedir. 1901 y\u0131l\u0131nda temett\u00fc \u00f6demelerine ba\u015flayan \u015firket, 120 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir kesintisiz \u00f6demeler yapmaktad\u0131r. 1990'lar\u0131n b\u00fcy\u00fck ila\u00e7 d\u00f6nemi s\u0131ras\u0131nda temett\u00fc b\u00fcy\u00fcmesi \u00f6zellikle g\u00fc\u00e7l\u00fcyd\u00fc (%13,2 y\u0131ll\u0131k), ancak son y\u0131llarda yakla\u015f\u0131k %2,5-3,8 y\u0131ll\u0131k b\u00fcy\u00fcmeye yava\u015flad\u0131. B\u00fcy\u00fcme oranlar\u0131ndaki bu yava\u015flamaya ra\u011fmen, mutlak temett\u00fc miktar\u0131 artmaya devam etti ve \u015firket, zorlu d\u00f6nemlerde bile y\u00f6netimin ilerici hissedar getirilerine olan ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6stererek, \u00fcst \u00fcste 14 y\u0131l boyunca temett\u00fc art\u0131\u015f\u0131 sa\u011flad\u0131."},{"question":"Pfizer \u00f6n\u00fcm\u00fczdeki y\u0131l temett\u00fcs\u00fcn\u00fc art\u0131racak m\u0131?","answer":"Mevcut finansal projeksiyonlar ve y\u00f6netim yorumlar\u0131na dayanarak, Pfizer'in COVID sonras\u0131 normalle\u015fme ile ilgili k\u0131sa vadeli gelir zorluklar\u0131na ra\u011fmen m\u00fctevaz\u0131 temett\u00fc art\u0131\u015flar\u0131 modelini s\u00fcrd\u00fcrmesi muhtemeldir. Analistler, \u00f6n\u00fcm\u00fczdeki 1-2 y\u0131l boyunca y\u0131ll\u0131k %1-2'lik muhafazakar bir art\u0131\u015f \u00f6ng\u00f6r\u00fcyor ve yeni \u00fcr\u00fcnlerin ivme kazanmas\u0131yla 3-5 y\u0131ll\u0131k zaman diliminde h\u0131zlanm\u0131\u015f b\u00fcy\u00fcme potansiyeli bulunuyor. Y\u00fckseltilmi\u015f \u00f6deme oran\u0131 (%68,7) \u00f6nemli art\u0131\u015flar \u00fczerinde baz\u0131 k\u0131s\u0131tlamalar yaratsa da, y\u00f6netim temett\u00fc istikrar\u0131n\u0131 sermaye tahsisi \u00f6nceli\u011fi olarak s\u00fcrekli vurgulam\u0131\u015f olup, bak\u0131m ve m\u00fctevaz\u0131 b\u00fcy\u00fcme en olas\u0131 senaryo haline gelmektedir."},{"question":"Pfizer'in temett\u00fcs\u00fc di\u011fer ila\u00e7 \u015firketleriyle nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r?","answer":"Pfizer'\u0131n %5,4 temett\u00fc getirisi, onu Johnson & Johnson (%3,1), Merck (%3,0) ve Bristol Myers Squibb (%4,2) gibi rakiplerini \u00f6nemli \u00f6l\u00e7\u00fcde a\u015farak en y\u00fcksek getirili b\u00fcy\u00fck sermayeli ila\u00e7 hisseleri aras\u0131nda konumland\u0131r\u0131yor. Bu y\u00fcksek getiri, sekt\u00f6r ortalamas\u0131n\u0131n (%51,2) \u00fczerinde bir \u00f6deme oran\u0131 (%68,7) ile birlikte geliyor ve baz\u0131 rakiplere k\u0131yasla agresif temett\u00fc b\u00fcy\u00fcmesi i\u00e7in daha az alan oldu\u011funu g\u00f6steriyor. Pfizer'\u0131n 14 y\u0131ll\u0131k temett\u00fc art\u0131\u015f\u0131 serisi, sekt\u00f6r ortalamas\u0131 olan 8 y\u0131l\u0131 a\u015farak, ortalaman\u0131n \u00fczerinde bir ilerici getiri taahh\u00fcd\u00fc sergiliyor. Ancak, Pfizer'\u0131n son temett\u00fc b\u00fcy\u00fcme oran\u0131 (son 3 y\u0131lda %3,8), AbbVie (%7,8) gibi b\u00fcy\u00fcme odakl\u0131 ila\u00e7 \u015firketlerinin gerisinde kal\u0131rken, GlaxoSmithKline (%1,2) gibi geleneksel ila\u00e7 isimlerini a\u015f\u0131yor."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Mevcut PFE hisse senedi temett\u00fc getirisi nedir?","answer":"Mevcut pfe hisse senedi temett\u00fc getirisi yakla\u015f\u0131k %5,4 seviyesinde olup, bu oran hem ila\u00e7 end\u00fcstrisi ortalamas\u0131 olan %2,8'in hem de S&P 500 ortalamas\u0131 olan %1,5'in olduk\u00e7a \u00fczerindedir. Bu y\u00fcksek getiri, Pfizer'\u0131n hissedar getirilerine olan ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 ve COVID sonras\u0131 gelir normalle\u015fmesiyle ilgili hisse fiyat\u0131 bask\u0131s\u0131n\u0131 yans\u0131tmaktad\u0131r. \u015eirket \u015fu anda \u00e7eyrek ba\u015f\u0131na hisse ba\u015f\u0131na 0,42 $ \u00f6demekte olup, bu y\u0131ll\u0131k 1,68 $'a denk gelmektedir. Bu ortalaman\u0131n \u00fczerindeki getiri, Pfizer'\u0131 piyasadaki en y\u00fcksek getirili b\u00fcy\u00fck \u00f6l\u00e7ekli ila\u00e7 hisseleri aras\u0131nda konumland\u0131rmaktad\u0131r."},{"question":"Bir sonraki pfe hisse senedi temett\u00fc \u00f6deme tarihi ne zaman?","answer":"Pfizer, Mart, Haziran, Eyl\u00fcl ve Aral\u0131k aylar\u0131nda \u00f6demelerle \u00fc\u00e7 ayl\u0131k bir temett\u00fc program\u0131 izler. Kesin pfe hisse senedi temett\u00fc tarihinden \u00f6nceki tarih her \u00e7eyrekte de\u011fi\u015fiklik g\u00f6sterir, ancak genellikle \u00f6deme tarihinden yakla\u015f\u0131k iki hafta \u00f6nce ger\u00e7ekle\u015fir. En g\u00fcncel bilgiler i\u00e7in yat\u0131r\u0131mc\u0131lar, bir sonraki temett\u00fc tarihinden \u00f6nce Pfizer'\u0131n yat\u0131r\u0131mc\u0131 ili\u015fkileri web sitesini veya finansal veri sa\u011flay\u0131c\u0131lar\u0131n\u0131 kontrol etmelidir. \u015eirket, temett\u00fc tarihlerini \u00f6nceden duyurma konusunda tutarl\u0131 bir ge\u00e7mi\u015fe sahiptir ve bu da yat\u0131r\u0131mc\u0131lar\u0131n takvim bazl\u0131 stratejiler planlamas\u0131na olanak tan\u0131r."},{"question":"Pfizer hisse senedi temett\u00fc ge\u00e7mi\u015fi zamanla nas\u0131l de\u011fi\u015fti?","answer":"Pfizer hisse senedi temett\u00fc ge\u00e7mi\u015fi, on y\u0131llar boyunca dikkate de\u011fer bir tutarl\u0131l\u0131k ve b\u00fcy\u00fcme g\u00f6stermektedir. 1901 y\u0131l\u0131nda temett\u00fc \u00f6demelerine ba\u015flayan \u015firket, 120 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir kesintisiz \u00f6demeler yapmaktad\u0131r. 1990'lar\u0131n b\u00fcy\u00fck ila\u00e7 d\u00f6nemi s\u0131ras\u0131nda temett\u00fc b\u00fcy\u00fcmesi \u00f6zellikle g\u00fc\u00e7l\u00fcyd\u00fc (%13,2 y\u0131ll\u0131k), ancak son y\u0131llarda yakla\u015f\u0131k %2,5-3,8 y\u0131ll\u0131k b\u00fcy\u00fcmeye yava\u015flad\u0131. B\u00fcy\u00fcme oranlar\u0131ndaki bu yava\u015flamaya ra\u011fmen, mutlak temett\u00fc miktar\u0131 artmaya devam etti ve \u015firket, zorlu d\u00f6nemlerde bile y\u00f6netimin ilerici hissedar getirilerine olan ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6stererek, \u00fcst \u00fcste 14 y\u0131l boyunca temett\u00fc art\u0131\u015f\u0131 sa\u011flad\u0131."},{"question":"Pfizer \u00f6n\u00fcm\u00fczdeki y\u0131l temett\u00fcs\u00fcn\u00fc art\u0131racak m\u0131?","answer":"Mevcut finansal projeksiyonlar ve y\u00f6netim yorumlar\u0131na dayanarak, Pfizer'in COVID sonras\u0131 normalle\u015fme ile ilgili k\u0131sa vadeli gelir zorluklar\u0131na ra\u011fmen m\u00fctevaz\u0131 temett\u00fc art\u0131\u015flar\u0131 modelini s\u00fcrd\u00fcrmesi muhtemeldir. Analistler, \u00f6n\u00fcm\u00fczdeki 1-2 y\u0131l boyunca y\u0131ll\u0131k %1-2'lik muhafazakar bir art\u0131\u015f \u00f6ng\u00f6r\u00fcyor ve yeni \u00fcr\u00fcnlerin ivme kazanmas\u0131yla 3-5 y\u0131ll\u0131k zaman diliminde h\u0131zlanm\u0131\u015f b\u00fcy\u00fcme potansiyeli bulunuyor. Y\u00fckseltilmi\u015f \u00f6deme oran\u0131 (%68,7) \u00f6nemli art\u0131\u015flar \u00fczerinde baz\u0131 k\u0131s\u0131tlamalar yaratsa da, y\u00f6netim temett\u00fc istikrar\u0131n\u0131 sermaye tahsisi \u00f6nceli\u011fi olarak s\u00fcrekli vurgulam\u0131\u015f olup, bak\u0131m ve m\u00fctevaz\u0131 b\u00fcy\u00fcme en olas\u0131 senaryo haline gelmektedir."},{"question":"Pfizer'in temett\u00fcs\u00fc di\u011fer ila\u00e7 \u015firketleriyle nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r?","answer":"Pfizer'\u0131n %5,4 temett\u00fc getirisi, onu Johnson & Johnson (%3,1), Merck (%3,0) ve Bristol Myers Squibb (%4,2) gibi rakiplerini \u00f6nemli \u00f6l\u00e7\u00fcde a\u015farak en y\u00fcksek getirili b\u00fcy\u00fck sermayeli ila\u00e7 hisseleri aras\u0131nda konumland\u0131r\u0131yor. Bu y\u00fcksek getiri, sekt\u00f6r ortalamas\u0131n\u0131n (%51,2) \u00fczerinde bir \u00f6deme oran\u0131 (%68,7) ile birlikte geliyor ve baz\u0131 rakiplere k\u0131yasla agresif temett\u00fc b\u00fcy\u00fcmesi i\u00e7in daha az alan oldu\u011funu g\u00f6steriyor. Pfizer'\u0131n 14 y\u0131ll\u0131k temett\u00fc art\u0131\u015f\u0131 serisi, sekt\u00f6r ortalamas\u0131 olan 8 y\u0131l\u0131 a\u015farak, ortalaman\u0131n \u00fczerinde bir ilerici getiri taahh\u00fcd\u00fc sergiliyor. Ancak, Pfizer'\u0131n son temett\u00fc b\u00fcy\u00fcme oran\u0131 (son 3 y\u0131lda %3,8), AbbVie (%7,8) gibi b\u00fcy\u00fcme odakl\u0131 ila\u00e7 \u015firketlerinin gerisinde kal\u0131rken, GlaxoSmithKline (%1,2) gibi geleneksel ila\u00e7 isimlerini a\u015f\u0131yor."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-19T05:00:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz\",\"datePublished\":\"2025-07-19T05:00:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/\"},\"wordCount\":12,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\",\"keywords\":[\"investment\",\"stock\",\"strategy\"],\"articleSection\":[\"Data\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/\",\"name\":\"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\",\"datePublished\":\"2025-07-19T05:00:31+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/","og_locale":"tr_TR","og_type":"article","og_title":"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-19T05:00:31+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz","datePublished":"2025-07-19T05:00:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/"},"wordCount":12,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","keywords":["investment","stock","strategy"],"articleSection":["Data"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/","name":"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","datePublished":"2025-07-19T05:00:31+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-dividend\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Pfizer Hisse Senedi Temett\u00fcs\u00fc: Gelir Odakl\u0131 Portf\u00f6yler \u0130\u00e7in Stratejik Analiz"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":314261,"slug":"pfizer-stock-dividend","post_title":"C\u1ed5 T\u1ee9c C\u1ed5 Phi\u1ebfu Pfizer: Ph\u00e2n T\u00edch Chi\u1ebfn L\u01b0\u1ee3c cho Danh M\u1ee5c \u0110\u1ea7u T\u01b0 T\u1eadp Trung V\u00e0o Thu Nh\u1eadp","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/data\/pfizer-stock-dividend\/"},"pt_AA":{"locale":"pt_AA","id":314256,"slug":"pfizer-stock-dividend","post_title":"Dividendo de A\u00e7\u00f5es da Pfizer: An\u00e1lise Estrat\u00e9gica para Portf\u00f3lios Focados em Renda","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/data\/pfizer-stock-dividend\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/314259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=314259"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/314259\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/259834"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=314259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=314259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=314259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}